Since 2012 Robert A. Bradway has held the position of Chairman & CEO at Amgen leading the way, for this biotechnology trailblazer during a time of expansion and groundbreaking advancements.
Robert’s journey with Amgen began in 2006 when he joined as Vice President of Operations Strategy. Over time he progressed to become the Chief Financial Officer. Finally assumed the role of Chief Executive Officer in 2011. With close to four decades of involvement, in the industry.
As Chairman and CEO, Bradway focused Amgen’s strategy on developing breakthrough medicines in high potential areas like cardiovascular disease, oncology and inflammation. Under his direction, Amgen launched new transformative therapies and expanded its global footprint, with revenues growing to over $25 billion.
Bradway prioritized investing in R&D and next-generation manufacturing technologies to drive future innovation. He also spearheaded strategic acquisitions, including the $13.4 billion purchase of Dezima Pharma to bolster Amgen’s cardiovascular portfolio.
Regarded for his calm demeanor and collaborative approach, Bradway is lauded for nurturing Amgen’s vibrant company culture. He remains committed to recruiting top talent and fostering inclusion.
Bradway’s visionary leadership and commercial expertise have been instrumental to Amgen’s continued success. He has solidified Amgen’s position as a pioneering force in the biopharma industry developing life-changing medicines that benefit society.
